Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
It aims to make the state-of-the-art modern and safe surgical care, typically available in super-speciality hospitals of big cities, accessible, affordable, standardized and integrated
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Supply increase to help meet growing global demand
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Subscribe To Our Newsletter & Stay Updated
